Leading Optometrists’ Network Chooses Medwave Sensor Technology

Medwave, Inc.
(Nasdaq: MDWV), the innovator in sensor-based, non-invasive blood-pressure
measuring solutions, announced today that Vision Source, the nation’s
premier network of independent doctors of optometry, has entered into a
purchasing agreement for Medwave’s Primo(TM) spot blood pressure monitoring

Representing the first major innovation to cuff- and mercury-based
blood pressure measurement in more than 100 years, Primo has gained rapid
acceptance among medical professionals and their patients due to its unique
combination of speed, accuracy, flexibility and comfort.

With more than 1,450 eye care centers (more than 2,700 doctors) in all
50 states, Vision Source facilities are known for their personal attention,
quality care and breakthrough technology. After evaluating Primo as a way
to obtain effective, accurate and comfortable blood pressure readings for
its patients, Vision Source observed that Primo accurately monitored even
some of the most challenging patient types — both large and small. Vision
Source patients also appreciated the fact that Primo obtained an accurate
blood pressure reading in only 12 seconds — and without the discomfort of
cuff-based devices.

“Vision Source is an innovative organization, and earning their trust
and faith in Primo is a great compliment,” said Tim O’Malley, Medwave, Inc.
President and CEO. “Primo offers many advantages over conventional,
cuff-based blood pressure products, and we’re thrilled that Vision Source
patients can now experience the difference. We are honored to add Vision
Source to our growing list of Primo users, and we look forward to
introducing all 1,450+ facilities to Primo.”

About Vision Source

Vision Source is the nation’s number one network of independent
optometrists with more than 2,700 doctors in over 1,450 practices across
the United States. With the combined buying power of a nationwide network,
Vision Source doctors are better able to control their materials costs and
offer their patients excellent value. Above all, each Vision Source
practice is dedicated to maintaining the special relationship between a
patient and his or her family eye doctor to ensure the best possible
vision- and eye-health care. For more information, visit

About Medwave

Medwave, Inc. develops, manufactures and distributes sensor-based
non-invasive blood pressure solutions. Medwave’s suite of products is
designed for use in hospitals, clinics, doctor’s offices and almost
anywhere blood pressure monitoring occurs. Medwave has the required
technology clearances to market its technology in the United States, Europe
and Asia. Medwave’s technology is installed in more than 500 hospitals and
clinics worldwide. Medwave trades on the NASDAQ small cap market under the
symbol MDWV. For more information, visit medwave.

Statements made in this release that are stated as expectations, plans,
anticipations, prospects or future estimates or which otherwise look
forward in time are considered “forward-looking statements” and involve a
variety of risks and uncertainties, known and unknown, which are likely to
affect the actual results. The following factors, among others, as well as
factors discussed in Medwave’s filings with the SEC, have affected and, in
the future, could affect Medwave’s actual results: resistance to the
acceptance of new medical products, the market acceptance of the Primo(TM)
system, the Vasotrac(R) system and other products of Medwave, hospital
budgeting cycles, the possibility of adverse or negative results or
commentary from clinical researchers or other users or evaluators of
Medwave’s products, Medwave’s success in creating effective distribution
channels for its products, Medwave’s ability to scale up its manufacturing
process, and delays in product development or enhancement or regulatory
approval. Consequently, no forward- looking statement can be guaranteed and
actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM),
Primo(TM), and Fusion(TM) are trademarks of Medwave, Inc.

Medwave, Inc.